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Moderate and severe neutropenia in patients with
systemic lupus erythematosus
D. Martı́nez-Baños, J. C. Crispı́n1, A. Lazo-Langner and
J. Sánchez-Guerrero1
Objectives. Neutropenia is an uncommon albeit relevant finding in patients with systemic lupus erythematosus (SLE). It has
been ascribed to several aetiologies and represents a challenging dilemma in which clinical findings, laboratory data and
medication history must be carefully evaluated. The aim of this work was to review the cases of moderate and severe
neutropenia in our cohort of SLE patients in order to identify predisposing factors, clinical outcomes and related prognostic
implications.
Methods. Thirty-three cases of neutropenia (neutrophil count <1000/ll) in patients with SLE were included. Sixty-five age-
and sex-matched patients with SLE served as controls. Information was obtained by medical chart review. Statistical analyses
included descriptive statistics, Student’s t-test, paired t-test, v2 or Fisher’s exact test, and logistic regression.
Results. Baseline characteristics did not differ between groups. Use of concomitant medications and immunosuppressive drugs,
as well as history of thrombocytopenia and central nervous system involvement, were associated with an increased risk for
developing neutropenia. Along with neutropenia, cases had lower haemoglobin and platelet values and higher levels of liver
enzymes. Moreover, disease activity was lower than in controls. One month after the neutropenia event, leucocyte and total
granulocyte counts were still lower in patients than in controls. Mortality did not differ between patients with neutropenia and
controls.
Conclusions. Most episodes of severe granulocytopenia in SLE patients occur as part of drug toxicity-induced medullar
hypoplasia.
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Systemic lupus erythematosus (SLE) is a chronic inflammatory
autoimmune disease with highly heterogeneous clinical manifesta-
tions. Haematological anomalies that include varying degrees
of anaemia, leucopenia and thrombocytopenia are commonly
found. Nevertheless, in the setting of SLE, cytopenias may be due
to several aetiologies. Disease activity, bone marrow failure, drug
toxicity, peripheral destruction, tumour infiltration and sepsis
have all been implicated [1, 2].
Even though neutropenia has been reported to occur as
a consequence of disease activity (probably related to anti-
granulocyte antibodies) [3], several potential causes of such
abnormality are frequently found. Interestingly, a positive correla-
tion has been found between high neutrophil clustering activity
(NCA) and low peripheral neutrophil count; likewise, high NCA
has been related to SLE activity. Whether this parameter will
help to discriminate between cytostatic drug-induced cytopenia,
SLE-induced cytopenia and the formation of intravascular
leucoaggregates remains to be proven [4, 5]. Another factor
worth considering is that many patients with SLE have been
exposed to alkylating drugs, which have been related to the
development of myelodysplastic syndromes and secondary acute
leukaemias [6]. Therefore, although frequently encountered
in clinical practice, cytopenias in patients with SLE represent
a challenging dilemma in which physicians must carefully evaluate
clinical findings and laboratory data, as well as present and past
medication. Hence, a bone marrow aspirate and core biopsy are
often required to elucidate the cause of cytopenias in the
background of SLE.
Due to inherent immune abnormalities and the immunosup-
pressive treatment they are exposed to, patients with SLE are
highly susceptible to infection [7]. The relationship between
neutrophil count and infection in patients with SLE is not well
established. Surprisingly, although low serum levels of soluble
Fc- receptor and high levels of granulocyte colony-stimulating
factor (G-CSF) have been recognized as risk factors for developing
infection in patients with SLE and neutropenia, absolute neutro-
phil count, bone marrow findings, measurements of the marrow
neutrophil reserve and serum levels of neutrophil granule compo-
nents have not [8–10].
The present work focuses specifically in neutropenia, an
infrequent finding in patients with SLE. In a prospective study
that included 126 patients with SLE, moderate and severe
neutropenia (less than 1000 and 500 polymorphonuclear leuco-
cytes/l, respectively) was reported in approximately 5% [11].
In summary, neutropenia is an uncommon, albeit relevant,
finding in patients with SLE that has been ascribed to several
aetiologies, and represents a complex clinical problem. The aim
of this work was to review the cases of moderate and severe
neutropenia in our SLE population, emphasizing disease activity,
drug associations and infectious complications, in order to identify
predisposing factors, clinical outcomes and related prognostic
implications.
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The present study was approved by the Institutional Committee on
Biomedical Research. Due to the retrospective and anonymous
nature of the study, informed patient consent was not required.
Patients
We identified all SLE patients who fulfilled the American College
of Rheumatology classification criteria [12] and were hospitalized
between 1984 and 2002 at the Instituto Nacional de Ciencias
Médicas y Nutrición Salvador Zubirán (INCMNSZ) with mod-
erate or severe neutropenia (less than 1000 and 500 neutrophils/l,
respectively). For each case, two SLE patients, matched by
age (±5 yr) and gender, hospitalized during the same period
(±1 month), for any reason except neutropenia, were selected as
controls.
Collected data
Sociodemographic and behavioural data were collected from
medical charts using a standardized format. Emphasis was made
on SLE course, including the number and type of accrued disease
criteria, date of diagnosis (defined as the time when four SLE
criteria were met), disease duration (defined as the period of time
from SLE diagnosis until index hospitalization), autoantibody
profile and treatment (including use of immunosuppressive drugs
and concomitant medications). Height and weight during index
hospitalization or the closest date were obtained, and body mass
index (BMI) was calculated as weight in kilograms divided by
the square of height in metres (kg/m2).
Attention was focused on three different time points: index
hospitalization and the two closest medical appointments
(prior to and subsequent to index hospitalization). At these
dates, information regarding clinical status, laboratory tests, SLE
treatment (including immunosuppressive agents and concomitant
medications) and disease activity was obtained; bone marrow
aspirate and core biopsy were reviewed when available. Disease
activity was assessed from medical notes using the SLE Disease
Activity Index (SLEDAI) [13] and a validated modified version
(Mex-SLEDAI) [14]; chronic damage was determined using the
Systemic Lupus International Collaborating Clinics/American
College of Rheumatology Damage Index (SLICC/ACR DI) [15].
Statistical analyses
Continuous variables were analysed using Student’s t-test, and
categorical variables using 2 or Fisher’s exact test. The association
between neutropenia and diverse variables was estimated by the
odds ratio (OR) and 95% confidence intervals (CIs). Clinically
relevant variables and variables with a P value 0.10 were entered
into a logistic regression model. The development of neutropenia
was considered the dependent variable. Statistical significance was
set at a P value 0.05, two-sided. All analyses were performed
using Intercooled STATA, version 7.0 (STATA Corporation,
College Station, TX, USA).
Results
Demographic and SLE characteristics
Thirty-three SLE patients (31 female) with moderate or severe
neutropenia and 65 SLE controls (62 female) were included.
Demographic characteristics were comparable in both groups
(Table 1).
The number of SLE criteria accumulated through the disease
course was similar in cases and controls (5.2±1.8 vs 4.9±1.9).
However, neurological criteria (27.2 vs 7.6%, P¼ 0.009) and
thrombocytopenia (33.3 vs 21.5%, P¼ 0.048) were significantly
more common in cases; history of haemolytic anaemia was more
commonly reported in patients with neutropenia (15.1 vs 7.6%),
although the difference did not reach statistical significance
(P¼ 0.06). The remaining clinical and serological characteristics
were similar in both groups (Table 2).
Clinical characteristics prior to the episode of neutropenia
Neutropenic and non-neutropenic patients had been seen 1 month
prior to the index hospitalization. At that visit, disease
activity was similar in both groups (SLEDAI 5.2±6.5 vs
6.9±5.6; Mex-SLEDAI 3.8±4.9 vs 5.4±3.9). Interestingly,
patients who would develop neutropenia had higher values of
mean corpuscular volume (MCV) and mean corpuscular haemo-
globin (MCH) (Table 3). With regard to treatment, the use
and dose of corticosteroids was similar in both groups. No
single immunosuppressive drug was significantly associated with
the development of neutropenia. Nevertheless, a non-significant
tendency towards a higher use of methotrexate in patients with
neutropenia was observed. When the use of any immunosuppres-
sive drug was considered as an independent variable, once more,
in the univariate analysis only a trend was observed towards
a more frequent use of these drugs in patients who would develop
neutropenia (60.6 vs 44.6%, P¼ 0.13; Table 4). Use of non-
steroidal anti-inflammatory drugs (NSAIDs) was similar in both
groups (data not shown).
Use of concomitant medications prior
to the development of neutropenia
Concomitant medication was defined as any drug other than
corticosteroids, immunosuppressive agents or NSAIDs taken
continuously during at least 2 weeks during the month prior
to the event of neutropenia. In the univariate analysis, the use of
both cisapride and phenytoin was found to be significantly higher
amongst patients within the neutropenia group (P¼ 0.04 and 0.02,
respectively). Also, a non-significant trend was observed with
amoxicillin-clavulanic acid and trimethoprim-sulphamethoxazole
(Table 4). However, in the multivariate analysis no single
TABLE 1. Demographic characteristics of study population
SLE patients
With neutropenia, n¼ 33 Without neutropenia, n¼ 65 P
Age at hospitalizationa (yr) 28.0±10.0 28.4±9.6 0.85
Gender (F/M) 31/2 62/3 1.00
Body mass indexa 23.9±6.4 23.8±4.0 0.88
Smoking (ever) 21.2% 33.8% 0.19
aMean±S.D.
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medication reached a significant level of association with the
presence of neutropenia. Nonetheless, when considered as a whole,
the use of any concomitant medication was more common in cases
than in controls (58 vs 20%, P<0.001) and it was associated with a
high risk for developing neutropenia (OR 16.5, 95% CI 2.9–94.4;
Tables 4 and 5).
Clinical characteristics during hospitalization
During hospital admission, infection was detected in a higher
proportion of patients with neutropenia than in controls
(75.7 vs 49.2%, P¼ 0.012). Conversely, disease activity scores
were significantly lower in cases than in controls (SLEDAI
5.8±4.7 vs 9.8±6.7, P¼ 0.001; Mex-SLEDAI 3.8±3.4 vs
6.4±4.3, P¼ 0.002).
Besides total leucocyte and neutrophil counts, lymphocyte count
was lower in neutropenic patients than in controls (627±616 vs
1165±979, P<0.001). Likewise, haemoglobin and platelet levels
were lower in neutropenic patients (haemoglobin 8.9±2.4 vs
11.1±2.4, P<0.001; platelets 138±111 vs 236±145, P¼ 0.001).
In addition, serum aminotransferases were elevated in cases
[SGOT (serum aspartate aminotransferase) 95.1±151.3 vs
42.7±50.9, P¼ 0.02; SGPT (serum alanine aminotransferase)
TABLE 3. Disease activity and laboratory parameters prior to and during the development of neutropenia
Prior to neutropenia Episode of neutropenia
With neutropenia Without neutropenia P With neutropenia Without neutropenia P
SLEDAI 5.2±6.5 6.9±5.6 0.27 5.8±4.7 9.8±6.7 0.001
Mex-SLEDAI 3.8±4.9 5.4±3.9 0.15 3.8±3.4 6.4±4.3 0.002
Infection (%) – – – 75.7 49.2 0.012
Haemoglobin 11.6±2.6 11.5±2.3 0.87 8.9±2.4 11.1±2.4 <0.001
Leucocytes 5908±3368 5925±2942 0.98 1071±654 8832±4692 <0.001
Neutrophils 3793±2627 4162±2336 0.56 307±253 7003±4134 <0.001
Lymphocytes 948±706 1143±768 0.30 627±616 1165±979 <0.001
Platelets 224±104 249±142 0.44 138±111 236±145 0.001
MCV 89.1±8.1 85.1±7.2 0.04 89.18±7.8 86.6±7.1 0.12
MCH 30.4±3 28.7±3.1 0.04 30.5±3.7 29.8±3.1 0.33
SGOT 60.4±145 45.1±66.8 0.65 95.1±151.3 42.7±50.9 0.02
SGPT 53.8±117 30.6±40.8 0.38 83.3±141.4 34.9±46.5 0.02
MCV, mean corpuscular volume; MCH, mean corpuscular haemoglobin; SGOT, serum aspartate aminotransferase; SGPT, serum alanine
aminotransferase.
TABLE 2. Clinical and serological characteristics of SLE in the study population
SLE patients
With neutropenia, n¼ 33 Without neutropenia, n¼ 65 P
SLE criteriaa 5.2±1.8 4.9±1.9 0.57
Age at SLE diagnosisa (yr) 25.9±10.6 25.7±10.1 0.92
Disease durationa (yr) 2.2±2.7 3.1±3.6 0.22
Length of follow-upa (yr) 2.5±4.2 2.6±3.9 0.85
Neurological criteria, n (%) 9 (27.2) 5 (7.6) 0.009
Thrombocytopenia, n (%) 11 (33.3) 14 (21.5) 0.048
Haemolytic anaemia, n (%) 5 (15.1) 5 (7.6) 0.06
SLICC/ACRDI scorea (first visit) 0.18±0.59 0.12±0.54 0.57
AAN, n (%) 22 (81.8) 35 (89.5) 0.50
Anti-dsDNA, n (%) 17 (73.9) 34 (87.1) 0.48
Anticardiolipin antibodies, n (%):
IgG 4 (23.5) 9 (32.1) 0.59
IgM 9 (52.9) 11 (39.2) 0.48
Decreased complement levels, n (%):
C3 13 (61.9) 23 (62.1) 0.81
C4 13 (68.4) 32 (86.4) 0.27
aMean±S.D.
TABLE 4. Use of prednisolone, immunosuppressants and concomitant







Prednisolone 78.1% 80.0% 0.83
Prednisolone (mg) (mean daily dose) 28.19±26 24.38±21.3 0.44
Azathioprine 36.3% 40.0% 0.73
Azathioprine (mg) (mean daily dose) 91.6±35.8 83.6±34.5 0.52
Cyclophosphamide p.o. 3.0% 1.5% 0.56
Cyclophosphamide i.v. 18.1% 10.7% 0.31
Methotrexate 9.1% 1.5% 0.07
Any immunosuppressive drug 60.6% 44.6% 0.13
Concomitant medications
Acyclovir 6.1% 1.5% 0.21
Allopurinol 3.0% 1.5% 0.62
Amoxicillin–clavulanic acid 9.1% 1.5% 0.07
Cisapride 6.1% 0 0.04
Phenytoin 12.1% 1.5% 0.02
Omeprazol 6.1% 1.5% 0.21
Trimethoprim–sulphamethoxazole 9.1% 1.5% 0.07
Any concomitant medication 58% 20.0% 0.001
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83.3±141.4 vs 34.9±46.5, P¼ 0.02] (Table 3). No differences in
renal function tests, antinuclear antibodies or complement levels
were detected (data not shown).
Bone marrow aspirates
A bone marrow aspirate was performed in 14 cases. Cellularity
was diminished in six patients, normal in five, increased in two
and could not be evaluated in one. Two patients showed
myeloid hyperplasia. Megakaryocytes were increased in one case
and decreased in two. Twelve patients showed changes consistent
with drug-induced marrow toxicity (granulocytic maturation
arrest at myelocyte stage, increase in eosinophils and dyserythro-
poiesis).
Outcome
The mean duration of neutropenia was 14.3±14 days; in nine cases
G-CSF was used. One month after the episode of neutropenia,
total leucocyte and neutrophil counts remained lower in cases than
in controls (leucocytes 4546±1592 vs 7421±3022, P<0.001;
neutrophils 2812±1381 vs 5263±2377, P<0.001). There were
no differences in new hospital admissions within the next month
following the neutropenia episode.
During hospitalization one death occurred in the control group
and two among the cases (only one directly related to neutropenia).
Multivariate analysis
The following variables were identified as independently associated
with the development of neutropenia: use of immunosuppressive
drugs (OR 4.81, 95% CI 1.1–20.8), history of central nervous
system manifestations (OR 5.04, 95% CI 1.2–20.8), history of
thrombocytopenia (OR 4.72, 95% CI 1.8–12.6) and use of
concomitant medications (OR 16.5, 95% CI 2.9–94.4) (Table 5).
The interaction between immunosuppressive drugs and concomi-
tant medication was not significant.
Discussion
In this study, we analysed the clinical and laboratory character-
istics of 33 patients with SLE who developed neutropenia. History
of thrombocytopenia and central nervous system (CNS) activity,
as well as use of immunosuppressive and concomitant medications,
were identified as independent risk factors for the development
of neutropenia. Thus, our results suggest that, in patients with
SLE, drug toxicity rather than disease activity is the most common
aetiology of neutropenia.
Leucopenia, first reported by Goeckerman in 1932 [11], is
a common finding in patients with SLE. As expected, in their
series, low leucocyte counts were primarily due to lymphopenia,
whilst neutrophil numbers were usually normal. Likewise, Michael
found that although 14% of untreated SLE patients had leucocyte
counts lower than 2000, only 2% had neutrophil counts below
1000 [16]. Alarcón-Segovia reported a patient with SLE who
simultaneously developed severe neutropenia and Coombs positive
haemolytic anaemia while receiving prymidone; both resolved
after the interruption of the drug [17]. Deleze et al. found a
direct relationship between anti-phospholipid antibodies (APLA)
and history of leucopenia in patients with SLE; although
they suggested APLA might be related to neutropenia in SLE
patients, their data were not conclusive [18]. This information
has indirectly dealt with the issue but, to the best of our knowledge,
no reported series has specifically focused on neutropenia in
patients with SLE.
In the present study, cases were compared against a robust
number of controls, matched by age, gender and hospitalization
date. Cases and controls comprised homogeneous and thus
comparable groups. This fact is well portrayed in Tables 1 and 2,
where no differences in demographic or SLE-related data were
found. When we compared the two groups, we found that patients
who developed neutropenia had a significantly higher frequency
of CNS and haematological activity than patients in the control
group. This, in addition to a higher exposure to immunosuppres-
sive agents and other drugs (referred to here as concomitant
medications), was significantly associated with the development
of neutropenia (Table 5). It may be argued that cases comprised
a group of patients with a more severe disease than controls.
However, disease activity and damage scores were similar in both
groups 1 month prior to the event (Tables 1 and 2). Further, it
is important to emphasize that other severe disease manifestations,
such as glomerulonephritis, that entail the use of intense immu-
nosuppression were not associated with the development of
neutropenia. Thus, data do not support the notion that neutro-
penia was due simply to immunosuppressive drug-induced bone
marrow toxicity, but was probably a consequence of a combina-
tion of factors including concomitant medication and perhaps
disease-related marrow damage.
The only differences between cases and controls 1 month prior
to the development of the neutropenic episode was that
cases exhibited higher median corpuscular volume and mean
corpuscular haemoglobin. Such differences may represent initial
toxicity-related changes, apparent before overt abnormalities
were detectable. During the episode of neutropenia, laboratory
abnormalities associated with drug toxicity were conspicuous.
Along with neutropenia, leucopenia, lymphopenia, thrombocyto-
penia and anaemia were present. Further, serum aminotransferases
were elevated in cases when compared with controls. These
findings are congruent with each other and with those reported
in bone marrow, where toxicity-related anomalies were evident in
most cases. Thus, bone marrow failure, probably related to
medication, was responsible for the cytopenia observed in most
patients. Such a notion was further supported by the results of
the multivariate analysis. Along with history of thrombocytopenia
and CNS activity, the use of immunosuppressive drugs, as well
as the use of concomitant medications, imposed the strongest risk
for the development of neutropenia.
In two cases (out 14 available aspirates), the bone marrow
aspirate exhibited myeloid hyperplasia. Although such a finding is
not specific (it may be found in patients exposed to drugs, infection
or in antibody-mediated neutropenia), it suggests that neutropenia
was not due to marrow failure. It is thus possible that in those
cases neutropenia was caused by SLE activity. Nevertheless,
neither activity scores nor disease activity-associated clinical or
laboratory findings differed in those two patients when compared
with the patients with marrow-toxicity induced neutropenia
(data not shown). This fact underscores the value of the bone
marrow aspirate in patients with SLE who develop neutropenia,
where no other clinical or laboratory finding is able to distinguish
between SLE activity and marrow toxicity-induced cytopenia.
At this point it is important to emphasize that in less than 10% of
the patients disease activity was identified as the probable cause
of neutropenia. This may be due to several factors. The patients
described were all under medical treatment at the time of the
TABLE 5. Variables associated with the development of neutropenia in
SLE patients
Variables OR (95% CI) P
Use of immunosuppressive drugs 4.81 (1.1–20.8) 0.035
History of CNS involvement 5.04 (1.2–20.8) 0.025
History of thrombocytopenia 4.72 (1.8–12.6) 0.002
Use of concomitant medications 16.5 (2.9–94.4) 0.002
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neutropenia event. Further, they were identified during a hospital
admission, which imposes an obvious selection bias in the study
population. More than 75% of them had an infectious process.
Thus, the event of neutropenia they underwent was probably more
severe or protracted than the cases seen on a daily basis that
spontaneously recover, without the need for hospital management.
Further, the most important drawback of the study, its retro-
spective design, must be considered. It imposes obvious limitations
in the information-gathering process. Thus, some data such as
serology could only be partially obtained.
We believe that our results stress the importance of cautious
use of medication in patients with SLE; they highlight that only
essential drugs should be used, because the addition of seemingly
innocuous medicines might trigger an event of neutropenia in
these patients [19]. Moreover, although our study did not consider
patients with other autoimmune diseases, it is reasonable to
consider that patients who receive immunosuppressive drugs
for other reasons might be at risk of developing neutropenia in
analogous scenarios.
Based on the results of this study, we may conclude that most
episodes of severe granulocytopenia in SLE patients occur as part
of drug toxicity-induced medullar hypoplasia.
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